Diabetes May Short Circuit Pembrolizumab Benefits in NSCLC

The new study shows a correlation between diabetes and poor outcomes for patients with metastatic non–small cell lung cancer (NSCLC) who received pembrolizumab.
Medscape Medical News

source https://www.medscape.com/viewarticle/993965?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

New AAFP practice guideline sets blood pressure targets for adults with hypertension

Heart Failure Care Outside of ICU Can Lower Cost